TMU
Owner
Tarbiat Modares University (TMU) is the owner of HEHP.
0.8
Cite Score
Volume 11, Issue 4 (2023)
Health Educ Health Promot 2023, 11(4): 609-614 |
Back to browse issues page
History
Received: 2023/08/12 | Accepted: 2023/11/8 | Published: 2023/11/18
Received: 2023/08/12 | Accepted: 2023/11/8 | Published: 2023/11/18
How to cite this article
Efficacy and Safety of Nanocurcumin in Patients with Heart Failure Reduced Ejection Fraction; A Randomized Placebo-Controlled Clinical Trial. Health Educ Health Promot 2023; 11 (4) :609-614
URL: http://hehp.modares.ac.ir/article-4-71033-en.html
URL: http://hehp.modares.ac.ir/article-4-71033-en.html
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Rights and permissions
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Authors
Abstract (1897 Views)
Aims: Heart failure reduced ejection fraction (HFrEF) is defined as symptoms, such as shortness of breath and edema with an ejection fraction of less than 40% in echocardiography. Regarding the pathogenesis, the role of inflammation is undeniable. Interleukin 6 (IL-6) is one of the pro-inflammatory cytokines that is important in cardiovascular disease and has a critical role in CAD. It is also related to complications caused by heart failure and mortality. Nanocurcumin is a polyphenol extracted from the rhizome of Curcuma longa (turmeric) with better bioavailability. Effects of nanocurcumin on the reduction of IL-6 and NT-proBNP in hospitalized HFrEF patients with acute decompensation were investigated.
Materials & Methods: Sixty patients with HFrEF admitted with acute heart failure were divided into the intervention group with the administration of 40 mg of nanocurcumin twice a day for seven days and the control group (placebo). The levels of electrolytes, creatinine, IL-6, and NT-proBNP were measured at baseline and after one week.
Findings: There was no statistically significant difference in the reduction in IL-6 and NT-proBNP levels in the intervention and control groups (p>0.05). Also, there was no significant difference in creatinine and estimated glomerular filtration rate in the two groups (p>0.05).
Conclusion: Nanocurcumin at a dose of 40 mg twice a day for seven days in patients with acute decompensated heart failure did not reduce IL-6 and NT-proBNP levels.
Materials & Methods: Sixty patients with HFrEF admitted with acute heart failure were divided into the intervention group with the administration of 40 mg of nanocurcumin twice a day for seven days and the control group (placebo). The levels of electrolytes, creatinine, IL-6, and NT-proBNP were measured at baseline and after one week.
Findings: There was no statistically significant difference in the reduction in IL-6 and NT-proBNP levels in the intervention and control groups (p>0.05). Also, there was no significant difference in creatinine and estimated glomerular filtration rate in the two groups (p>0.05).
Conclusion: Nanocurcumin at a dose of 40 mg twice a day for seven days in patients with acute decompensated heart failure did not reduce IL-6 and NT-proBNP levels.
Keywords:
| | Full-Text (HTML) (503 Views)